You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Hematologic Malignancies Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Market Analysis and Insights: Global Hematologic Malignancies Market
The research report studies the Hematologic Malignancies market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Hematologic Malignancies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Hematologic Malignancies Scope and Segment
The global Hematologic Malignancies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hematologic Malignancies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Leukemia
Lymphoma
Multiple Myeloma
Others
by Application, this report covers the following segments
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Global Hematologic Malignancies market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Hematologic Malignancies key players in this market include:
Pfizer, Inc.
F. Hoffmann-LA Roche ltd
Sanofi-Aventis
Bristol-Myers Squibb Company
AbbVie, Inc.
Novartis AG
GlaxoSmithKline PLC
Celgene Corporation
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company limited
1 Market Overview of Hematologic Malignancies
1.1 Hematologic Malignancies Market Overview
1.1.1 Hematologic Malignancies Product Scope
1.1.2 Hematologic Malignancies Market Status and Outlook
1.2 Global Hematologic Malignancies Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Hematologic Malignancies Market Size by Region (2016-2027)
1.4 Global Hematologic Malignancies Historic Market Size by Region (2016-2021)
1.5 Global Hematologic Malignancies Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Hematologic Malignancies Market Size (2016-2027)
1.6.1 North America Hematologic Malignancies Market Size (2016-2027)
1.6.2 Europe Hematologic Malignancies Market Size (2016-2027)
1.6.3 Asia-Pacific Hematologic Malignancies Market Size (2016-2027)
1.6.4 Latin America Hematologic Malignancies Market Size (2016-2027)
1.6.5 Middle East & Africa Hematologic Malignancies Market Size (2016-2027)
2 Hematologic Malignancies Market Overview by Type
2.1 Global Hematologic Malignancies Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Hematologic Malignancies Historic Market Size by Type (2016-2021)
2.3 Global Hematologic Malignancies Forecasted Market Size by Type (2022-2027)
2.4 Leukemia
2.5 Lymphoma
2.6 Multiple Myeloma
2.7 Others
3 Hematologic Malignancies Market Overview by Application
3.1 Global Hematologic Malignancies Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Hematologic Malignancies Historic Market Size by Application (2016-2021)
3.3 Global Hematologic Malignancies Forecasted Market Size by Application (2022-2027)
3.4 Chemotherapy
3.5 Radiotherapy
3.6 Immunotherapy
3.7 Stem Cell Transplantation
3.8 Others
4 Hematologic Malignancies Competition Analysis by Players
4.1 Global Hematologic Malignancies Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hematologic Malignancies as of 2020)
4.3 Date of Key Players Enter into Hematologic Malignancies Market
4.4 Global Top Players Hematologic Malignancies Headquarters and Area Served
4.5 Key Players Hematologic Malignancies Product Solution and Service
4.6 Competitive Status
4.6.1 Hematologic Malignancies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Pfizer Inc.
5.1.1 Pfizer Inc. Profile
5.1.2 Pfizer Inc. Main Business
5.1.3 Pfizer Inc. Hematologic Malignancies Products, Services and Solutions
5.1.4 Pfizer Inc. Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.1.5 Pfizer Inc. Recent Developments
5.2 F. Hoffmann-LA Roche ltd
5.2.1 F. Hoffmann-LA Roche ltd Profile
5.2.2 F. Hoffmann-LA Roche ltd Main Business
5.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Products, Services and Solutions
5.2.4 F. Hoffmann-LA Roche ltd Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.2.5 F. Hoffmann-LA Roche ltd Recent Developments
5.3 Sanofi-Aventis
5.3.1 Sanofi-Aventis Profile
5.3.2 Sanofi-Aventis Main Business
5.3.3 Sanofi-Aventis Hematologic Malignancies Products, Services and Solutions
5.3.4 Sanofi-Aventis Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.3.5 Bristol-Myers Squibb Company Recent Developments
5.4 Bristol-Myers Squibb Company
5.4.1 Bristol-Myers Squibb Company Profile
5.4.2 Bristol-Myers Squibb Company Main Business
5.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Company Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.4.5 Bristol-Myers Squibb Company Recent Developments
5.5 AbbVie Inc.
5.5.1 AbbVie Inc. Profile
5.5.2 AbbVie Inc. Main Business
5.5.3 AbbVie Inc. Hematologic Malignancies Products, Services and Solutions
5.5.4 AbbVie Inc. Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.5.5 AbbVie Inc. Recent Developments
5.6 Novartis AG
5.6.1 Novartis AG Profile
5.6.2 Novartis AG Main Business
5.6.3 Novartis AG Hematologic Malignancies Products, Services and Solutions
5.6.4 Novartis AG Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.6.5 Novartis AG Recent Developments
5.7 GlaxoSmithKline PLC
5.7.1 GlaxoSmithKline PLC Profile
5.7.2 GlaxoSmithKline PLC Main Business
5.7.3 GlaxoSmithKline PLC Hematologic Malignancies Products, Services and Solutions
5.7.4 GlaxoSmithKline PLC Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.7.5 GlaxoSmithKline PLC Recent Developments
5.8 Celgene Corporation
5.8.1 Celgene Corporation Profile
5.8.2 Celgene Corporation Main Business
5.8.3 Celgene Corporation Hematologic Malignancies Products, Services and Solutions
5.8.4 Celgene Corporation Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.8.5 Celgene Corporation Recent Developments
5.9 Johnson & Johnson Services Inc.
5.9.1 Johnson & Johnson Services Inc. Profile
5.9.2 Johnson & Johnson Services Inc. Main Business
5.9.3 Johnson & Johnson Services Inc. Hematologic Malignancies Products, Services and Solutions
5.9.4 Johnson & Johnson Services Inc. Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.9.5 Johnson & Johnson Services Inc. Recent Developments
5.10 Takeda Pharmaceutical Company limited
5.10.1 Takeda Pharmaceutical Company limited Profile
5.10.2 Takeda Pharmaceutical Company limited Main Business
5.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Products, Services and Solutions
5.10.4 Takeda Pharmaceutical Company limited Hematologic Malignancies Revenue (US$ Million) & (2016-2021)
5.10.5 Takeda Pharmaceutical Company limited Recent Developments
6 North America
6.1 North America Hematologic Malignancies Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Hematologic Malignancies Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hematologic Malignancies Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hematologic Malignancies Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hematologic Malignancies Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hematologic Malignancies Market Dynamics
11.1 Hematologic Malignancies Industry Trends
11.2 Hematologic Malignancies Market Drivers
11.3 Hematologic Malignancies Market Challenges
11.4 Hematologic Malignancies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Au
  • FORMAT: PDF
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 125